Our mission is to improve the lives of patients suffering from autoimmune diseases

About Us

Oppilan Pharma is a clinical-stage biopharmaceutical company focused on developing novel small molecule therapeutics for the treatment of autoimmune diseases.

Our lead drug candidate, OPL-002, is a potent and selective modulator of sphingosine 1 phosphate receptor subtype 1 (S1P1) under development for the treatment of inflammatory bowel disease. We initiated a Phase 1 clinical study with OPL-002 in December 2018.

Our Focus

About Inflammatory Bowel Disease
About Inflammatory Bowel Disease
About Inflammatory Bowel Disease
Inflammatory bowel disease, including Crohn’s disease and ulcerative colitis, represents a group of autoimmune disorders characterized by chronic inflammation of the digestive tract. These disorders affect as many as 1.6 million Americans and patients are often diagnosed before the age of 35. Despite current treatment options, there remains a significant unmet need for well-tolerated, safe and effective oral therapies.
About the S1P1 receptor
About the S1P1 receptor
About the S1P1 receptor
The S1P1 receptor regulates lymphocyte trafficking from the lymph nodes to the peripheral blood. S1P1 modulators block the receptor’s function resulting in sequestration of lymphocytes in the lymph nodes. This reduces the number of circulating immune cells capable of producing chronic inflammation in the digestive tract.
About Our Lead Program
About Our Lead Program
About Our Lead Program
Our lead drug candidate, OPL-002, is a potent and selective modulator of sphingosine 1 phosphate receptor subtype 1 (S1P1) designed for the treatment of IBD and other autoimmune disorders. OPL-002 has a unique pharmacokinetic and pharmacodynamic profile, which we believe will result in improved safety and tolerability for patients. We initiated a Phase 1 clinical study with OPL-002 in December 2018.

Our Focus

About Inflammatory Bowel Disease
About Inflammatory Bowel Disease
About Inflammatory Bowel Disease
Inflammatory bowel disease, including Crohn’s disease and ulcerative colitis, represents a group of autoimmune disorders characterized by chronic inflammation of the digestive tract. These disorders affect as many as 1.6 million Americans and patients are often diagnosed before the age of 35. Despite current treatment options, there remains a significant unmet need for well-tolerated, safe and effective oral therapies.
About the S1P1 receptor
About the S1P1 receptor
About the S1P1 receptor
Sphingosine 1 phosphate receptor subtype 1 (S1P1) regulates lymphocyte trafficking from the lymph nodes to the peripheral blood. S1P1 modulators block the receptor’s function resulting in sequestration of lymphocytes in the lymph nodes. This reduces the number of circulating immune cells capable of producing auto-immunological responses in the digestive tract.

Our Team

Management
Board of Directors
Clinical Advisory Board
  • William Sandborn, MD (Chairman)
    William Sandborn, MD (Chairman) Chief, Division of Gastroenterology at UCSD
  • Bruce Sands, MD
    Bruce Sands, MD Chief, Division of Gastroenterology at Icahn School of Medicine at Mount Sinai
  • Julián Panés, MD
    Julián Panés, MD Chief of Department of Gastroenterology at Hospital Clínic de Barcelona

News

Our Investors

investors-newscienceventures2

New Science Ventures

New Science Ventures, LLC (NSV) is a New York-based venture capital firm that invests in companies using novel scientific approaches in the life sciences sector (biotech, pharma and medical devices) and the information technology sector (semiconductors, photonics and advanced materials).  NSV was founded in 2004 by Somu Subramaniam, Managing Partner, and Tom Lavin, Partner, and has invested approximately $750 million in both early and late stage companies located in the United States, Europe and India.  For more information, visit www.newscienceventures.com.

investors-thirdpointventures2

Third Point Ventures

Third Point Ventures is the emerging technology investment arm of Third Point LLC.  Third Point LLC is an SEC-registered investment adviser based in New York City.  The firm was founded in 1995 by Daniel S. Loeb, who serves as its CEO and oversees all investment activity.  Third Point employs an event-driven, value-oriented investment style.  Third Point’s team includes professionals focused on investment activity, risk management and trading.  This team is supported by highly experienced accounting, operations, investor relations and marketing, and legal and compliance professionals.  For more information, visit www.thirdpointventures.com.